Title of study


PRODIA

Acronym for cohort


Name of Principal Investigator - Title


Dr

Name of Principal Investigator - First name


Charlotte

Name of Principal Investigator - Last name


Teunissen

Address of institution -Institution


Vumc

Address of institution - Street address


Boelelaan 1117

Address of institution - City


Amsterdam

Address of institution - Postcode


1081 HV

Country


Netherlands

Website


Contact email


[email protected]

Funding source


ZonMW

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)


To identify and validate novel CSF biomarkers for differential diagnosis of dementia, with a pathological relation.

Q2b. What distinguishes this case-control study from other studies?


We identify biomarkers via merging of tissue and CSF proteomics datasets, which is an unique approach.

Q3a. i) Number of publications that involve use of your cohort to date


Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)


Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study


We expect to identify biomarkers for use in clinical practise for diagnosis of dementia patients.

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


50

Q4a. Study criteria: what is the age range of participants at recruitment? To:


80

Q4b. Study criteria: what are the inclusion criteria?


Amsterdam dementia cohort, so retrospective and biobanked samples of patients with defined clinical diagnosis of dementias.

Q4c. Study criteria: what are the exclusion criteria?


Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?


1-1,000

Q5b. What is the expected number of control participants?


200-500

Q6a. Please describe what measures are used to characterise participants


clinical diagnosis, MMSE

Q6b. Are there additional measures for participants with the clinical disorder?


Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


No

If YES please specify


Q7. What is the study design?


Prospective cohort

Q8. Are your cases matched by


Age| Sex

Q9a. Does your study includes a specialised subset of control participants?


Yes

Q9b. If your study includes a specialised subset of control participants please describe


individuals with subjective memory complaints

Q10a. Is data collection for this study


Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Yes - intend to apply for funding

Q11. Are data collected


Through links to other records or registers(Amsterdam dementia cohort)

Q12. Is there a system in place to enable re-contact with patients for future studies?


Yes (participants have given permission to be re-contacted via the PIs)

Q13a. Please give information on data stored in a database (1)


Data summarised in database

% Available


100

Q13a. Please give information on data stored in a database (2)


No

% Available


Q13a. Please give information on data stored in a database (3)


No

% Available


Q13a. Please give information on data stored in a database (4)


No

% Available


Q13a. Please give information on data stored in a database (5)


Yes

% Available


100

Please specify language used


Access

% Available


100

Q13b. Please give information on how data is held as individual records


No

% Available


Q14a. Are data available to other groups?


Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Apply to PI or co-ordinator at resource

Q15. What data sharing policy is specified as a condition of use?


No policy exists

Q16a. Are tissues/samples/DNA available to other groups?


Yes

Q16b i) If yes, please describe below


Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Living donors: cerebro-spinal fluid

Q16b. ii) In what form are tissues/samples/DNA supplied?


Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples: plasma| Secondary samples: DNA

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


Yes

Q17. Is information on biological characteristics available to other groups?


Yes, for all the cohort

Export as PDF